Navigation Links
ULURU Inc. Announces Issuance of Notice of Allowance for Nanoparticle Aggregate Patent
Date:12/17/2007

ADDISON, Texas, Dec. 17 /PRNewswire-FirstCall/ -- ULURU Inc. (Amex: ULU) today announced that it has received a Notice of Allowance from the United States Patent and Trademark Office for its nanoparticle aggregate patent.

This patent covers the underlying science behind the Company's nanoparticle aggregate technology; consequently, this is a very important asset in our patent portfolio.

Commenting on the issuance of the Notice of Allowance for the patent, Kerry P. Gray, President and Chief Executive Officer of ULURU, stated, "This Notice of Allowance is an important step in securing intellectual property protection for the range of products we anticipate developing from our nanoparticle aggregate technology. To further secure our patent position we have also filed additional patents to protect the wound care, breast implant and dermal filler applications of the technology."

On issuance, this patent will expire in 2022. The subsequently filed patent applications which broaden our patent position could extend the patent life for the wound care and breast implant product portfolios until the end of 2026.

Mr. Gray added, "The value of this family of patents is further enhanced by the substantial term remaining prior to patent expiration, which gives the company significant time to realize the full economic benefits of these important assets."

About ULURU Inc.:

ULURU Inc. is an emerging specialty pharmaceutical company focused on the development of a portfolio of wound management, plastic surgery and oral care products to provide patients and consumers improved clinical outcomes through controlled delivery utilizing its innovative transmucosal delivery system and Hydrogel Nanoparticle Aggregate technology. For further information about ULURU Inc., please visit our website at http://www.uluruinc.com.

This press release contains certain statements that are forward-lo
'/>"/>

SOURCE ULURU Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine news :

1. ULURU Inc. to Present at UBS Global Life Sciences Conference 2007
2. ULURU Inc. Announces Odd-Lot Buy Back Offer
3. ULURU Inc. Announces Conference Call to Discuss Financial Results for the Third Quarter Ended September 30, 2007 and Provide a Business Update
4. ULURU Inc. Reports Third Quarter 2007 Results
5. HHS Announces $75 Million in Supplemental Funding to States for Pandemic Flu Preparedness
6. CRC Health Group Announces Acquisition of Bayside Marin Recovery Center, San Rafael
7. UHW Announces: Antelope Valley Hospital Caregivers and Board Vote to Ratify First Union Contract With SEIU UHW-West
8. HEI, Inc. Announces Sale of RFID Division Assets
9. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)
10. Mettler-Toledo International Inc. Announces Webcast of Presentation at Thomas Weisel Partners 2007 Healthcare Conference
11. Z Trim Announces Revocation of Gregory Halpern Severence Agreement
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/12/2008)...ONT, Calif., May 12 /PRNewswire/ -- Keck Graduate ...008, commencement ceremony will feature,the gradua...tudent, Eric,Tan, and the unveiling of KGI,s first... of Eric,s achievement in becoming the,first gradu..., KGI,s senior,vice president for academic affairs...
(Date:5/12/2008)... VA Nurses Are ,the Compassionate Heart, of System... The Department of,Veterans Affairs (VA), the nati...ional Nurses Week by honoring six of its top profe...rt of VA,s world-class health care,system," stated... "A great,deal of our reputation comes from the pe...
(Date:5/12/2008)... NASDAQ: CRME TSX: COM, VANCOUVER...Corp.,(NASDAQ: CRME / TSX: COM) today announced th...quarter of 2008 on the afternoon of Tuesday, May 1...and webcast at 4:30pm,Eastern (1:30pm Pacific) on ...onference call, please dial 416-641-6117 or,866-29...
(Date:5/12/2008)...lease is available in French . , Montreal, May...n that the administration of sildenafil protects t... This study was led by Dr. Christine Des Rosiers f...t Institute, in collaboration with Dr. Basil Petro...ty Health Centre (MUHC) and Dr. Christian Deschepp...
Breaking Medicine News(10 mins):Health News:KGI 2008 Commencement Features First PhD Graduate, Biotech Painting 2Health News:Cardiome To Release 2008 First Quarter Results 2Health News:Cardiome To Release 2008 First Quarter Results 3Health News:Cardiome To Release 2008 First Quarter Results 4Health News:New approach to protect the hearts of patients with muscular dystrophy 2Health News:New approach to protect the hearts of patients with muscular dystrophy 3
...rley Street plastic surgeon plans to sell a contro...de him and his wife “look years younger”.// He as... his memory and removed wrinkles, and made his wif... enough to be his daughter. The plastic surgeon a...
... respiratory specialists declared yesterday that c...million annually.// Lost of productivity when suf...n, while the health service industry loses ?104mil...itish Thoracic Society (BTS), this figure does not...
...y known as Mandrax, is a "downer" used to get reli...ide effects, however, have led to the banning of t...roduced in the 1960s into the pharmaceutical marke...was also used for other medicinal uses, especially...
... claimed to prevent more sudden deaths than defibr...ted defibrillators according to US scientists.// R... compared such preventive strategies by food suppl...n a computer-simulated community of 100,000 people...
Other Medicine News:Health News:Look younger with HGH!! 2Health News:Delhi Police Seized 4,400 kg of Banned Drug Mandrax 2
(Date:5/8/2008)...IELD, Ill., May 8 /- Siemen...(R) Holdings (LabCorp(R)) today announced,that the...s future,possibilities to co-develop new clinical ...tics, metabolic syndrome, oncology and diabetes. U... on developing new tests that,could make the bigge...
(Date:5/8/2008)...AVEN, Conn., May 8 /- VION ...nced the start of an investigator-sponsored,Phase ...loretazine(R),(VNP40101M) in combination with cyta...ed acute myelogenous leukemia (AML) and high-risk,...g conducted under the,direction of Ellen K. Ritchi...
(Date:5/8/2008)...Data Presentations to Focus on Use of Pro-Healing ...lerate Dual-Antiplatelet Therapy, HONG KONG, May ... both,a randomized pilot study and the real-world ... R stent, the world,s first pro-healing stent, wil... 2008 in Barcelona, Spain., The symposium, titled...
(Date:5/8/2008)...NGTON, Del., May 8 /- Astra...of a supplemental New Drug Application,(sNDA) to t...OQUEL XR(TM),(quetiapine fumarate) Extended-Releas...neralized anxiety disorder (GAD), including mainte...approval has been sought for an,atypical antipsych...
Breaking Medicine Technology:Siemens and LabCorp Enter Agreement to Co-Develop New Clinical Diagnostic Tests 2Siemens and LabCorp Enter Agreement to Co-Develop New Clinical Diagnostic Tests 3Siemens and LabCorp Enter Agreement to Co-Develop New Clinical Diagnostic Tests 4Vion Pharmaceuticals Announces Initiation of Clinical Trial of Cloretazine(R) (VNP40101M) in Combination with Cytarabine 2Vion Pharmaceuticals Announces Initiation of Clinical Trial of Cloretazine(R) (VNP40101M) in Combination with Cytarabine 3Data from Randomized Pilot Study, Real-World Use of OrbusNeich's Genous(TM) Bio-engineered R stent(TM) to be Presented in Symposium at EuroPCR 2008 2AstraZeneca Submits sNDA for SEROQUEL XR(TM) for the Treatment of Generalized Anxiety Disorder - a First for the Atypical Antipsychotic Class of Medicines 2AstraZeneca Submits sNDA for SEROQUEL XR(TM) for the Treatment of Generalized Anxiety Disorder - a First for the Atypical Antipsychotic Class of Medicines 3AstraZeneca Submits sNDA for SEROQUEL XR(TM) for the Treatment of Generalized Anxiety Disorder - a First for the Atypical Antipsychotic Class of Medicines 4AstraZeneca Submits sNDA for SEROQUEL XR(TM) for the Treatment of Generalized Anxiety Disorder - a First for the Atypical Antipsychotic Class of Medicines 5AstraZeneca Submits sNDA for SEROQUEL XR(TM) for the Treatment of Generalized Anxiety Disorder - a First for the Atypical Antipsychotic Class of Medicines 6AstraZeneca Submits sNDA for SEROQUEL XR(TM) for the Treatment of Generalized Anxiety Disorder - a First for the Atypical Antipsychotic Class of Medicines 7AstraZeneca Submits sNDA for SEROQUEL XR(TM) for the Treatment of Generalized Anxiety Disorder - a First for the Atypical Antipsychotic Class of Medicines 8Depression and Alzheimers Risk Linked 16158 1Depression and Alzheimers Risk Linked 16158 2Depression and Alzheimers Risk Linked 16158 3War between the sexes begins before twins birth TAU researchers say 2794 1War between the sexes begins before twins birth TAU researchers say 2794 2U Iowa study finds biological link between pain and fatigue 2792 1U Iowa study finds biological link between pain and fatigue 2792 25W Public Relations Presents the 2008 Body Beautiful Media Symposium Benefiting The Skin Cancer Foundation 16157 15W Public Relations Presents the 2008 Body Beautiful Media Symposium Benefiting The Skin Cancer Foundation 16157 25W Public Relations Presents the 2008 Body Beautiful Media Symposium Benefiting The Skin Cancer Foundation 16157 3
... symptoms of SLE,disease at 52 Weeks and demonstra... weeks-, ROCKVILLE, Md., June 14, 2007 /PRNewswire...nnounced the presentation of Phase 2,trial data de...ficantly reduced disease activity across multiple ... quality of life in,patients with active systemic ...
...- CombinatoRx,Incorporated (NASDAQ: CRXX) today a...ed to its immuno-inflammatory product,candidates, ...t,Rheumatism (EULAR) Annual Congress of Rheumatolo... CRx-102 , In a poster entitled "Inhibition of Mac...CRx-102, a Novel Synergistic Combination,Drug Cand...
Other Medicine Technology:Human Genome Sciences Reports That a Phase 2 Study of LymphoStat-B,Showed Significant Reductions in Disease Activity in Patients with,Active Systemic Lupus Erythematosus 2Human Genome Sciences Reports That a Phase 2 Study of LymphoStat-B,Showed Significant Reductions in Disease Activity in Patients with,Active Systemic Lupus Erythematosus 3Human Genome Sciences Reports That a Phase 2 Study of LymphoStat-B,Showed Significant Reductions in Disease Activity in Patients with,Active Systemic Lupus Erythematosus 4Human Genome Sciences Reports That a Phase 2 Study of LymphoStat-B,Showed Significant Reductions in Disease Activity in Patients with,Active Systemic Lupus Erythematosus 5Human Genome Sciences Reports That a Phase 2 Study of LymphoStat-B,Showed Significant Reductions in Disease Activity in Patients with,Active Systemic Lupus Erythematosus 6Human Genome Sciences Reports That a Phase 2 Study of LymphoStat-B,Showed Significant Reductions in Disease Activity in Patients with,Active Systemic Lupus Erythematosus 7Human Genome Sciences Reports That a Phase 2 Study of LymphoStat-B,Showed Significant Reductions in Disease Activity in Patients with,Active Systemic Lupus Erythematosus 8Additional Data on CombinatoRx Drug Candidates CRx-102 and CRx-139,Presented at EULAR 2Additional Data on CombinatoRx Drug Candidates CRx-102 and CRx-139,Presented at EULAR 3Additional Data on CombinatoRx Drug Candidates CRx-102 and CRx-139,Presented at EULAR 4
Level 1 enables hospitals to standardize all multiparameter patient monitors to a single temperature monitoring series. Our temperature monitoring disposale probes and reusable cables are superior in
Level 1 enables hospitals to standardize all multiparameter patient monitors to a single temperature monitoring series. Our temperature monitoring disposale probes and reusable cables are superior in
...tbeat. The bodys warmth beneath drapes. The life-g...ns are yours to guard, measure, stabilize and cros...roducts helps you do your job, giving you the info... precise management of your patients stability dur...
...aser system used in neurophysiology for studying e...just the amplitude and/or the duration of the stim...laser emission in an ongoing manner by acting on t...r include the high repeatability of the impulses, ...
Medicine Products: